Identification

Name
Fluspirilene
Accession Number
DB04842
Type
Small Molecule
Groups
Approved
Description

A long-acting injectable antipsychotic agent used for chronic schizophrenia.

Structure
Thumb
Synonyms
  • Fluspirileno
  • Fluspirilenum
  • Imap
External IDs
Lopac-F-100 / MCN-JR-6218 / R 6218
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Imap Forte Inj 10mg/mlSuspension10 mgIntramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1982-12-311998-08-13Canada
Imap Inj 2mg/mlSuspension2 mgIntramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1977-12-311998-03-12Canada
International/Other Brands
Imap (Janssen) / lmap (McNeil) / Redeptin (SKF)
Categories
UNII
C5QA4GLR9M
CAS number
1841-19-6
Weight
Average: 475.5727
Monoisotopic: 475.243519039
Chemical Formula
C29H31F2N3O
InChI Key
QOYHHIBFXOOADH-UHFFFAOYSA-N
InChI
InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
IUPAC Name
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
SMILES
FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1

Pharmacology

Indication

Used for the treatment of schizophrenia.

Structured Indications
Not Available
Pharmacodynamics

Fluspirilene is a relatively long-acting injectable depot antipsychotic drug used for schizophrenia. Fluspirilene does not differ greatly from other depot antipsychotics (fluphenazine decanoate, fluphenazine enathate, perphenazine onanthat, pipotiazine undecylenate) with respect to treatment efficacy, response or tolerability. Outcomes suggest that fluspirilene does not differ significantly from oral antipsychotics or in different weekly regimens, although much cannot be inferred because of the shortage of trials.

Mechanism of action
TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
UVoltage-dependent calcium channel gamma-1 subunit
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineFluspirilene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineFluspirilene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFluspirilene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluspirilene.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluspirilene.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluspirilene.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fluspirilene.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluspirilene.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fluspirilene.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluspirilene.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluspirilene.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amperozide.Experimental
AmphetamineFluspirilene may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluspirilene.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fluspirilene.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Azaperone.Vet Approved
AzelastineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluspirilene.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluspirilene.Approved
BenzphetamineFluspirilene may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluspirilene.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluspirilene.Approved, Investigational
BuprenorphineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluspirilene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluspirilene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluspirilene.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluspirilene.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluspirilene.Approved
CanertinibThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluspirilene.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fluspirilene.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluspirilene.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluspirilene.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluspirilene.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluspirilene.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Chlorphenamine.Approved
ChlorphentermineFluspirilene may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluspirilene.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluspirilene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluspirilene.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Fluspirilene.Approved
ClemastineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Fluspirilene is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluspirilene.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluspirilene.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluspirilene.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluspirilene.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluspirilene.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluspirilene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluspirilene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluspirilene.Approved
DetomidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluspirilene.Approved, Vet Approved
DextroamphetamineFluspirilene may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluspirilene.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluspirilene.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluspirilene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fluspirilene.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluspirilene.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Diethyl ether.Experimental
DiethylpropionFluspirilene may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluspirilene.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluspirilene.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluspirilene.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluspirilene.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluspirilene.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluspirilene.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fluspirilene is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluspirilene.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluspirilene.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluspirilene.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluspirilene.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluspirilene.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluspirilene.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluspirilene.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fluspirilene.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluspirilene.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluspirilene.Approved
EthanolFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluspirilene.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluspirilene.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluspirilene.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluspirilene.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluspirilene.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluspirilene.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluspirilene.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluspirilene.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluspirilene.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluspirilene.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluspirilene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluspirilene.Approved, Illicit
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluspirilene.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fluspirilene.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluspirilene.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluspirilene.Approved, Illicit
GepefrineFluspirilene may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluspirilene.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluspirilene.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluspirilene.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluspirilene.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fluspirilene.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluspirilene.Approved
HydrocodoneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene.Approved, Illicit
HydroxyamphetamineFluspirilene may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Indiplon.Investigational
Iofetamine I-123Fluspirilene may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluspirilene.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fluspirilene.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluspirilene.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluspirilene.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluspirilene.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluspirilene.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Fluspirilene.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluspirilene.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluspirilene.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluspirilene.Approved, Investigational
LisdexamfetamineFluspirilene may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Fluspirilene.Approved
LofentanilThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluspirilene.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluspirilene.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluspirilene.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluspirilene.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fluspirilene.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Melperone.Approved
MephedroneFluspirilene may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineFluspirilene may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluspirilene.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Meptazinol.Experimental
MequitazineFluspirilene may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluspirilene.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fluspirilene.Approved, Illicit
MethamphetamineFluspirilene may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluspirilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluspirilene.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluspirilene.Approved
MethotrimeprazineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluspirilene.Approved, Vet Approved
MethoxyphenamineFluspirilene may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fluspirilene.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluspirilene.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene.Approved, Investigational
MetyrosineFluspirilene may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene.Approved, Illicit
MidomafetamineFluspirilene may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Fluspirilene.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
MirtazapineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAFluspirilene may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluspirilene.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluspirilene.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluspirilene.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluspirilene.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fluspirilene.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluspirilene.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluspirilene.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluspirilene.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluspirilene.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluspirilene.Approved
OpiumThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Opium.Approved, Illicit
OrphenadrineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluspirilene.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluspirilene.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluspirilene.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluspirilene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluspirilene.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluspirilene.Approved
ParaldehydeFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fluspirilene.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluspirilene.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
PerazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluspirilene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluspirilene.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluspirilene.Approved
PhenibutThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluspirilene.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenoxyethanol.Approved
PhentermineFluspirilene may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluspirilene.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pomalidomide.Approved
PramipexoleFluspirilene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluspirilene.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluspirilene.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluspirilene.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluspirilene.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluspirilene.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluspirilene.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fluspirilene.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluspirilene.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fluspirilene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Fluspirilene is combined with PSD502.Investigational
PseudoephedrineFluspirilene may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluspirilene.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluspirilene.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluspirilene.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluspirilene.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluspirilene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluspirilene.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluspirilene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ritanserin.Investigational
RitobegronFluspirilene may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluspirilene.Approved
RomifidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Romifidine.Vet Approved
RopiniroleFluspirilene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluspirilene.Approved
RotigotineFluspirilene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluspirilene.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluspirilene.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluspirilene.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Fluspirilene.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluspirilene.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
StiripentolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluspirilene.Approved, Investigational
SuvorexantFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluspirilene.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluspirilene.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluspirilene.Approved
TetracaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrodotoxin.Investigational
ThalidomideFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluspirilene.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluspirilene.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluspirilene.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluspirilene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluspirilene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluspirilene.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluspirilene.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluspirilene.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluspirilene.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluspirilene.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluspirilene.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Fluspirilene.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fluspirilene.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluspirilene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluspirilene.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluspirilene.Approved, Investigational
ZolpidemFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluspirilene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluspirilene.Approved, Investigational
Food Interactions
  • Avoid alcohol.

References

Synthesis Reference

Janssen, P.A.J.; U.S. Patent 3,238,216; March 1, 1966; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.

US3238216
General References
Not Available
External Links
Human Metabolome Database
HMDB15590
KEGG Drug
D02629
PubChem Compound
3396
PubChem Substance
46508202
ChemSpider
3279
BindingDB
26948
ChEBI
93369
ChEMBL
CHEMBL46516
Therapeutic Targets Database
DAP000980
PharmGKB
PA162565878
IUPHAR
85
Guide to Pharmacology
GtP Drug Page
Wikipedia
Fluspirilene
ATC Codes
N05AG01 — Fluspirilene
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular10 mg
SuspensionIntramuscular2 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)187.5-190Janssen, P.A.J.; U.S. Patent 3,238,216; March 1, 1966; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
water solubility10 mg/L (at 25 °C)MERCK INDEX (1996)
logP5.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00167 mg/mLALOGPS
logP5.18ALOGPS
logP5.78ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.99ChemAxon
pKa (Strongest Basic)9.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.58 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity135.27 m3·mol-1ChemAxon
Polarizability50.88 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9807
Blood Brain Barrier+0.9713
Caco-2 permeable-0.68
P-glycoprotein substrateSubstrate0.7042
P-glycoprotein inhibitor IInhibitor0.9082
P-glycoprotein inhibitor IIInhibitor0.8257
Renal organic cation transporterInhibitor0.5978
CYP450 2C9 substrateNon-substrate0.835
CYP450 2D6 substrateNon-substrate0.5726
CYP450 3A4 substrateSubstrate0.645
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9209
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.6989
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7201
Ames testNon AMES toxic0.5428
CarcinogenicityNon-carcinogens0.8871
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6387 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8401
hERG inhibition (predictor II)Inhibitor0.9014
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006t-9636300000-e318745a9958ecf316e7

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylbutylamines / Phenylimidazolidines / Alpha amino acids and derivatives / Azaspirodecane derivatives / Dialkylarylamines / Aniline and substituted anilines / Fluorobenzenes / Aralkylamines / Imidazolidinones / Aryl fluorides
show 10 more
Substituents
Diphenylmethane / Phenylbutylamine / Phenylimidazolidine / Alpha-amino acid or derivatives / Azaspirodecane / Aniline or substituted anilines / Dialkylarylamine / Aralkylamine / Halobenzene / Fluorobenzene
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Wang SJ: Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. [PubMed:11842444]
  5. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name
CACNG1
Uniprot ID
Q06432
Uniprot Name
Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight
25028.105 Da
References
  1. Kenny BA, Fraser S, Kilpatrick AT, Spedding M: Selective antagonism of calcium channel activators by fluspirilene. Br J Pharmacol. 1990 Jun;100(2):211-6. [PubMed:1696149]
  2. Wang SJ: Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. [PubMed:11842444]

Drug created on September 27, 2007 07:56 / Updated on October 02, 2017 05:39